About this episode
Will tough times continue for psychedelic stocks? (1:50) Analyst Alex Carchidi shares his views on the sector and specific stocks like Compass Pathways (4:20), Atai and Cybin (19:50) and the inevitability of big pharma buying up assets (32:10). Transcripts available on Seeking Alpha Cybin: A Leading Early-Stage Psychedelics Play American Medical Association approves CPT code for psychedelic therapies FDA drafts new guidance on psychedelic research Psychedelic Sunday: Scrutinizing Psychedelic Stocks